Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trevogrumab
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Trevogrumab is a fully human monoclonal antibody that targets growth/differentiation factor 8 (GDF8), also known as myostatin. By inhibiting myostatin, trevogrumab is designed to increase muscle mass and strength, making it a potential therapy for conditions characterized by muscle wasting such as sarcopenia (age-related loss of skeletal muscle mass), obesity (to preserve lean mass during weight loss), and musculoskeletal disorders. It is being developed using Regeneron's VelocImmune technology platform. Trevogrumab has been studied both alone and in combination with other agents, such as semaglutide (a GLP-1 receptor agonist) and garetosmab (an anti-activin A antibody), particularly in the context of obesity to enhance fat loss while preserving or increasing lean body mass[2][3][6][8].
- Other names
- trevogrumab
02
Targets
GDF8 (Myostatin)
Beyond the preview
Go deeper on trevogrumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trevogrumab.